Corticotropin

Generic Name: Corticotropin

Brand Names: Acthar, Cortrophin

Drug Type: Biotech

CAS Number: 12427-33-7

Unique Ingredient Identifier: K0U68Q2TXA

Background: Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.

Indication: For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.

Purified corticotropin for injection is indicated for a variety of allergic and autoimmune conditions.

Associated Conditions: Acute Gouty Arthritis, Allergic Conjunctivitis (AC), Ankylosing Spondylitis (AS), Atopic Dermatitis, Chorioretinitis, Choroiditis, Infantile Spasms (IS), Iridocyclitis, Iritis, Keratitis, Multiple sclerosis exacerbation, Optic Neuritis, Polymyositis, Psoriatic Arthritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Serum Sickness, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Anterior eye segment inflammation, Severe Erythema multiforme, Severe Psoriasis, Symptomatic Sarcoidosis, Systemic Dermatomyositis

Clinical Trials

ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)

Phase 2

Conditions: Uveitis

Interventions: Drug: ACTH gel

First Posted Date: 2016-10-12

Last Posted Date: 2018-09-27

Lead Sponsor: Quan Dong Nguyen

Target Recruit Count: 36

Registration Number: NCT02931175

Locations: 🇺🇸
Retina Vitreous Associates, Medical Group, Los Angeles, California, United States
🇺🇸
Stanford University, Palo Alto, California, United States

ACTHAR Therapy for Central Nervous System Sarcoidosis

Phase 4

Withdrawn

Conditions: Sarcoidosis

Interventions: Drug: Repository Corticotropin Injection

First Posted Date: 2016-09-30

Last Posted Date: 2020-11-20

Lead Sponsor: The Cleveland Clinic

Registration Number: NCT02920710

Locations: 🇺🇸
Cleveland Clinic Main Campus, Cleveland, Ohio, United States

Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis

Phase 4

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Placebo
Drug: Acthar Gel

First Posted Date: 2016-09-29

Last Posted Date: 2020-03-31

Lead Sponsor: Mallinckrodt

Target Recruit Count: 259

Registration Number: NCT02919761

Locations: 🇺🇸
June DO, PC, Lansing, Michigan, United States
🇺🇸
Physician Research Collaboration, LLC, Lincoln, Nebraska, United States
🇲🇽
SMIQ, Querétaro, Mexico

and more 55 locations

Acthar SLE (Systemic Lupus Erythematosus)

Phase 4

Withdrawn

Conditions: Systemic Lupus Erythematosus (SLE)
Repository Corticotropin Injection

Interventions: Drug: Acthar high dose (80 U)
Drug: Acthar low dose (40 U)

First Posted Date: 2016-05-20

Last Posted Date: 2019-09-13

Lead Sponsor: NYU Langone Health

Registration Number: NCT02779153

Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis

Phase 4

Terminated

Conditions: Uveitis

Interventions: Drug: Acthar

First Posted Date: 2016-05-12

Last Posted Date: 2018-10-01

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 2

Registration Number: NCT02769702

Locations: 🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

Not Applicable

Completed

Conditions: Panuveitis
Anterior Uveitis
Ocular Sarcoidosis

Interventions: Drug: Repository Corticotropin Injection
Drug: Repository Corticotropin Injection -Treatment Extension

First Posted Date: 2016-03-31

Last Posted Date: 2023-11-14

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 9

Registration Number: NCT02725177

Locations: 🇺🇸
Cleveland Clinical Foundation, Cleveland, Ohio, United States

Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation

Phase 3

Active, not recruiting

Conditions: FSGS

Interventions: Drug: Acthar

First Posted Date: 2016-02-17

Last Posted Date: 2024-04-08

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 20

Registration Number: NCT02683889

Locations: 🇺🇸
Medstar Georgetown Transplant Institute, Washington, District of Columbia, United States

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria

Phase 4

Completed

Conditions: Idiopathic Focal Segmental Glomerulosclerosis

Interventions: Drug: Acthar Gel

First Posted Date: 2015-12-17

Last Posted Date: 2021-08-04

Lead Sponsor: Mallinckrodt ARD LLC

Target Recruit Count: 63

Registration Number: NCT02633046

Locations: 🇦🇺
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇺🇸
NKDHC Medical Research Services, LLC, Las Vegas, Nevada, United States
🇺🇸
University of Cincinnati Physicians Company, LLC, Cincinnati, Ohio, United States

and more 43 locations

Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar

Phase 4

Terminated

Conditions: Transplant Glomerulopathy

Interventions: Drug: Acthar gel

First Posted Date: 2015-09-11

Last Posted Date: 2022-10-06

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 6

Registration Number: NCT02546492

Locations: 🇺🇸
Unniversity of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
University of Alabama School of Medicine, Alabama Transplant Center, Birmingham, Alabama, United States

Use of Acthar in Rheumatoid Arthritis (RA) Related Flares

Phase 4

Recruiting

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: Acthar

First Posted Date: 2015-09-04

Last Posted Date: 2025-04-02

Lead Sponsor: Veena Ranganath, MD, MS

Target Recruit Count: 40

Registration Number: NCT02541955

Locations: 🇺🇸
UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy